Optimization studies on design and evaluation of orodispersible pediatric formulation of indomethacin.
In the present study, the aim was to optimize an orodispersible formulation of indomethacin using a combined approach of subliming agent and superdisintegrant. The tablets were made by non-aqueous wet granulation technique with superdisintegrant incorporated both intragranularly and extragranularly. A 2(3) factorial design was used to investigate the effects amount of subliming agents namely camphor and ammonium bicarbonate and taste masking and soothening hydrophilic agent mannitol as independent variables and disintegration time and crushing strength as dependent responses. The volatilization time of eight hours at 50 degrees C was optimized by conducting solid-state kinetic studies of optimized formulations. Optimized orodispersible tablets were evaluated for wetting time, water absorption ratio, porosity and in vitro and in vivo disintegration tests. Results show that higher levels of camphor and mannitol and a lower level of ammonium bicarbonate is desirable for orodispersion. Scanning electron microscopy (SEM) revealed the porous surface morphology and kinetic digital images substantiated the orodispersible property. Differential Scanning Calorimetry (DSC) studies exhibited physiochemical compatibility between indomethacin and various excipients used in the tablet formulation. Stability studies carried out as per ICH Q(1) A guidelines suggested the stable formulations for the tested time period of 6 months. The systematic approach of using subliming and disintegrating agents helped in achieving a stable, optimized orodispersible formulation, which could be industrially viable.
Singh
Jashanjit
J
Department of Pharmaceutics, Rajiv Academy For Pharmacy, NH#2, Delhi- Mathura bypass, PO Chattikkara, Mathura, 281001 Uttar Pradesh, India.
Philip
Anil K
AK
Pathak
Kamla
K
D000284:Administration, Oral; D020650:Combinatorial Chemistry Techniques / Q000379:methods*; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding / Q000379:methods*; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D005079:Excipients / Q000737:chemistry*; D007213:Indomethacin / Q000008:administration & dosage / Q000737:chemistry*; D010372:Pediatrics; D011786:Quality Control; D013607:Tablets / Q000737:chemistry
D004337:Drug Carriers; D005079:Excipients; D013607:Tablets; D007213:Indomethacin